Shanghai Runda Med Tech Co (603108) - Total Liabilities
Based on the latest financial reports, Shanghai Runda Med Tech Co (603108) has total liabilities worth CN¥8.41 Billion CNY (≈ $1.23 Billion USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shanghai Runda Med Tech Co - Total Liabilities Trend (2014–2024)
This chart illustrates how Shanghai Runda Med Tech Co's total liabilities have evolved over time, based on quarterly financial data. See 603108 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Shanghai Runda Med Tech Co Competitors by Total Liabilities
The table below lists competitors of Shanghai Runda Med Tech Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Zhejiang Hailide New Material Co Ltd
SHE:002206
|
China | CN¥3.87 Billion |
|
Stx Engine
KO:077970
|
Korea | ₩814.56 Billion |
|
Tian Jin Motor Dies Co Ltd
SHE:002510
|
China | CN¥3.51 Billion |
|
Matrix Design Co. Ltd. A
SHE:301365
|
China | CN¥355.71 Million |
|
Yunnan Hongxiang Yixintang
SHE:002727
|
China | CN¥8.05 Billion |
|
Aker Biomarine AS
OL:AKBM
|
Norway | Nkr237.50 Million |
|
Jiangsu Riying Electns Co Ltd
SHG:603286
|
China | CN¥1.04 Billion |
|
Kayne Anderson BDC, Inc.
NYSE:KBDC
|
USA | $1.17 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Shanghai Runda Med Tech Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 603108 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shanghai Runda Med Tech Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shanghai Runda Med Tech Co (2014–2024)
The table below shows the annual total liabilities of Shanghai Runda Med Tech Co from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥8.70 Billion ≈ $1.27 Billion |
-1.82% |
| 2023-12-31 | CN¥8.86 Billion ≈ $1.30 Billion |
-6.80% |
| 2022-12-31 | CN¥9.51 Billion ≈ $1.39 Billion |
+24.72% |
| 2021-12-31 | CN¥7.62 Billion ≈ $1.12 Billion |
+25.07% |
| 2020-12-31 | CN¥6.10 Billion ≈ $892.08 Million |
+10.51% |
| 2019-12-31 | CN¥5.52 Billion ≈ $807.23 Million |
+25.03% |
| 2018-12-31 | CN¥4.41 Billion ≈ $645.64 Million |
+0.81% |
| 2017-12-31 | CN¥4.38 Billion ≈ $640.46 Million |
+132.09% |
| 2016-12-31 | CN¥1.89 Billion ≈ $275.95 Million |
+146.42% |
| 2015-12-31 | CN¥765.27 Million ≈ $111.98 Million |
+25.60% |
| 2014-12-31 | CN¥609.27 Million ≈ $89.16 Million |
-- |
About Shanghai Runda Med Tech Co
Shanghai Runda Medical Technology Co., Ltd. provides medical laboratory services primarily in China. It also engages in the research and development, manufacturing, sale, and service of in vitro diagnostic products, including reagents and other consumables; medical solutions to help healthcare professionals in the areas of diabetes, POCT, clinical chemistry, and immunoassay; professional technica… Read more